BMO Capital Markets started coverage on shares of Tcr2 Therapeutics (NASDAQ:TCRR) in a research report sent to investors on Monday morning, MarketBeat Ratings reports. The brokerage issued an outperform rating and a $37.00 target price on the stock.

TCRR opened at $18.24 on Monday. Tcr2 Therapeutics has a fifty-two week low of $14.80 and a fifty-two week high of $25.47.

In other news, major shareholder Upnorth Investment Ltd acquired 200,000 shares of Tcr2 Therapeutics stock in a transaction dated Tuesday, February 19th. The shares were bought at an average cost of $15.00 per share, with a total value of $3,000,000.00. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Morana Jovan-Embiricos acquired 666,667 shares of Tcr2 Therapeutics stock in a transaction dated Tuesday, February 19th. The stock was purchased at an average cost of $15.00 per share, for a total transaction of $10,000,005.00. The disclosure for this purchase can be found here.

Tcr2 Therapeutics Company Profile

TCR2 Therapeutics Inc, a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. Its product candidates in pipeline comprise TC-210 mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors; TC-220 that targets MUC16 positive solid tumors; and TC-310 and TC-410 dual TRuC-T cell programs targeting CD19/22 and MSLN/MUC16, as well as TC-110 mono TRuC-T cells targeting CD19-positive B-Cell hematological malignancies.

Featured Article: Channel Trading

Analyst Recommendations for Tcr2 Therapeutics (NASDAQ:TCRR)

Receive News & Ratings for Tcr2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tcr2 Therapeutics and related companies with's FREE daily email newsletter.